We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

1 hedge funds and large institutions have $0 invested in Acceleron Pharma in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 330 → 1 (-329)

100% less funds holding in top 10

Funds holding in top 10: 13 → 0 (-13)

100% less capital invested

Capital invested by funds: $9.13B → $0 (-$9.13B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 325

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-329
Holders Change %
-99.7%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
325
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$923M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$848M
3
ACA
Avoro Capital Advisors
New York
-$688M
4
BlackRock
BlackRock
New York
-$684M
5
FCM
Farallon Capital Management
California
-$373M
Name Holding Trade Value Shares
Change 		Change in
Stake
KFI
301
Key Financial Inc
Pennsylvania
– -$15K -85 Closed
Bessemer Group
302
Bessemer Group
New Jersey
– -$12K -70 Closed
CAPTRUST Financial Advisors
303
CAPTRUST Financial Advisors
North Carolina
– -$10K -58 Closed
VCM
304
Versant Capital Management
Arizona
– -$10K -57 Closed
HNB
305
Huntington National Bank
Ohio
– -$9.59K -55 -96%
EARNEST Partners
306
EARNEST Partners
Georgia
– -$8K -47 Closed
EWA
307
Evolution Wealth Advisors
Florida
– -$8K -47 Closed
PCG
308
Private Capital Group
Connecticut
– -$8K -45 Closed
S
309
SignatureFD
Georgia
– -$7K -42 Closed
MAM
310
Meeder Asset Management
Ohio
– -$7K -39 Closed
QCG
311
Quadrant Capital Group
Ohio
– -$6K -37 Closed
PA
312
Parallel Advisors
California
– -$6K -36 Closed
GWSG
313
GPS Wealth Strategies Group
Colorado
– -$6K -35 Closed
Rockefeller Capital Management
314
Rockefeller Capital Management
New York
– -$4K -29 Closed
FMII
315
Farmers & Merchants Investments Inc
Nebraska
– -$4K -23 Closed
EW
316
Evoke Wealth
California
– -$3K -20 Closed
NFSG
317
Newbridge Financial Services Group
Florida
– -$3K -19 Closed
CWP
318
Concord Wealth Partners
Virginia
– -$3K -16 Closed
First Manhattan
319
First Manhattan
New York
– -$2K -16 Closed
ED
320
Exane Derivatives
France
– -$2.24K -13 Closed
TFO
321
Tarbox Family Office
California
– -$2K -10 Closed
BIA
322
Bell Investment Advisors
California
– -$1K -4 Closed
CI Investments Inc
323
CI Investments Inc
Ontario, Canada
– -$1K -3 Closed
NFG
324
Next Financial Group
Texas
– -$1K -3 Closed
9 10 11 12
13

XLRN Hedge Fund Activity: Q4 2021 in Review

1 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2021, worth a combined $0 — down 100% from $9.13B a quarter earlier.

Sellers outnumbered buyers: 325 funds closed out of XLRN and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $923M sold.

  • 1 institutional investor held Acceleron Pharma (XLRN) as of Q4 2021, down from 330 in Q3 2021.
  • Funds reported $0 of Acceleron Pharma stock for Q4 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Acceleron Pharma positions in Q4 2021 and 325 closed out, a net change of -325 holders.
  • The largest Acceleron Pharma seller in Q4 2021 was T. Rowe Price Associates, an estimated $923M sold.

Based on aggregated 13F filings for Q4 2021.